



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

Subthreshold micropulse yellow (577nm) laser versus intravitreal Ranibizumab in treatment of center involving diabetic macular oedema

THESIS

*Submitted FOR PARTIAL FULFILMENT OF
MD DEGREE IN OPHTHALMOLOGY*

By

Esraa Abdelhakeem Mohamed El-Sayed Diab

*M.B.B.Ch, M.Sc., Ophthalmology
Faculty of medicine - Ain Shams University*

Supervised by

Prof. Dr. Alaa Fathy Mahmoud

*Professor of Ophthalmology
Faculty of Medicine - Ain Shams University*

Ass. Prof. Mohamed Abdel-hakim Zaki

*Assistant Professor of Ophthalmology
Faculty of Medicine - Ain Shams University*

Ass. Prof. Ahmed Abdel-aleem Mohamed

*Assistant Professor of Ophthalmology
Faculty of Medicine - Ain Shams University*

Dr. Mohamed Hanafy Abdel-aziz

*Lecturer of Ophthalmology
Faculty of Medicine - Ain Shams University*

Faculty of Medicine
Ain-Shams University
Cairo
Egypt
2020

List of Contents

Title	Page No.
List of abbreviations	II
List of figures	IV
List of tables	VII
Introduction	1
➤ Diabetic macular oedema	3
➤ Subthreshold micropulse laser	8
➤ Anti- vascular endothelial growth factors	19
Aim of the work	32
Review of literature	33
Patients and methods	59
Results	67
Discussion	91
Conclusion	99
Summary	100
References	102
Arabic summary	١

List of abbreviations

BCVA	Best corrected visual acuity
BRB	Blood retinal barrier
CAMs	Cell adhesion molecules
CFT	Central foveal thickness
CI	Confidence interval
CMT	Central macular thickness
CMV	Central macular volume
CSME	Clinically significant macular oedema
CST	Central subfield thicknesss
CW	Continuous wave
DC	Duty cycle
DM	Diabetes mellitus
DME	Diabetic macular oedema
DR	Diabetic retinopathy
DRCR	Diabetic retinopathy clinical research network
DRS	Diabetic retinopathy study
EPM	Endpoint management
ETDRS	Early treatment diabetic retinopathy study
FAF	Fundus auto-fluorescence
FAZ	Foveal avascular zone
FcRn	Neonatal Fc receptor
FFA	Fundus fluorescein angiography
FT	Foveal thickness
HD-SDM	High density subthreshold diode micropulse
HSP	Heat shock proteins
ICAM	Intracellular adhesion molecules
IOP	Intraocular pressure
IVI	Intravitreal injection
MAPK	Mitogen activating protein kinase
mETDRS	Modified early treatment diabetic retinopathy study
mfERG	Multifocal electroretinogram

MPL	Micropulse laser
ND-SDM	Normal density subthreshold diode micropulse
NPDR	Non-proliferative diabetic retinopathy
NVAMD	Neovascular age related macular degeneration
OCT	Optical coherence tomography
PASCAL	Pattern Scan Laser
PEDF	Pigment epithelium derived growth factor
PDR	Proliferative diabetic retinopathy
PKC	Protein kinase C
PLGF	Placental growth factor
PPV	Pars plana vitrectomy
PRP	Pan retinal photocoagulation
RCTs	Randomized controlled trials
ROS	Reactive oxygen species
RPE	Retinal pigment epithelium
SD OCT	Spectral domain optical coherence tomography
SDM	Subthreshold diode micropulse
SRT	Selective retinal therapy
STMPL	Subthreshold micropulse laser
TGF-β	Transforming growth factor beta
VE	Vascular endothelial
VEGF	Vascular endothelium growth factor
VEGFRs	Vascular endothelial growth factor receptors
VVOs	Vesiculo-vacuolar organelles
ZO	Zonula occludin

List of figures

Fig. No.	Title	Page NO.
Fig. (1)	Blood retinal barrier	3
Fig. (2)	Pathophysiological mechanisms leading to macular oedema	4
Fig.(3)	Mechanisms induced by hyperglycemia in the retina leading to DME	5
Fig. (4)	The different pathways in the development of DME	6
Fig. (5)	RPE porcine explants irradiated with 140 mJ/cm ² per pulse stained with the vitality marker Calcein AM showing vital cells with green fluorescence	13
Fig. (6)	RPE explant picture taken before, 200 ns after (b) and 1 s after (c) irradiation within the area	14
Fig. (7)	Nondamaging retinal laser therapy with Endpoint Management	15
Fig. (8)	Mechanism of action of continuous wave laser versus subthreshold micropulse laser treatment	17
Fig. (9)	Endothelium transport mechanism (Vesiculovacuolar organelles)	21
Fig. (10)	Schematic representation of tight junctions and adherens junctions in endothelial cells	22
Fig. (11)	Pre and post STMPL red free fundus photographs and FFA	34
Fig. (12)	Baseline and 12-month follow-up of a patient with CSME treated with SDM photocoagulation	42
Fig. (13)	Absorption of visible wavelengths by ocular pigments	43

Fig. (14)	Color fundus photograph of patient's right eye with DME	44
Fig. (15)	OCT and FAF of one of the study eyes	57
Fig. (16)	Easyret 577nm yellow laser photocoagulator, Quantel medical	65
Fig. (17)	Consort flow diagram	68
Fig. (18)	Chart showing the mean BCVA at baseline and during follow up	71
Fig. (19)	Chart showing the number of lines gained at 3,6, 9 and 12 months of follow up	72
Fig. (20)	Chart showing percentage of stabilization, improvement and reduction of BCVA in the MPL at 3, 6, 9 and 12 months in the MPL group	73
Fig. (21)	Chart showing percentage of stabilization, improvement and reduction of BCVA in the MPL at 3, 6, 9 and 12 months in the IVL group	74
Fig. (22)	Column chart showing the percentage of eyes showing a BCVA of $\geq 20/40$ at 3, 6, 9 and 12 months respectively in group A.	75
Fig. (23)	Column chart showing the percentage of eyes showing a BCVA of $\geq 20/40$ at 3, 6, 9 and 12 months respectively in group B.	75
Fig. (24)	Chart showing the mean CST at baseline and during follow up in both study groups	76
Fig. (25)	The mean reduction in CST at 3, 6, 9 and 12 months in the two study groups	78
Fig. (26)	Percentage of reduction in CST (μm) at 3, 6, 9 and 12 months in the two study groups.	79

Fig. (27)	Chart showing the percentage of study eyes showing resolution of macular oedema after one session versus after two sessions of MPL	80
Fig. (28)	OCT scan of the macula at baseline (A) and at 3months (B) after one session of STMPL	81
Fig. (29)	OCT scan of the macula at baseline (A) and after 12 months (B)	81
Fig. (30)	Primary analysis treatment effect estimates with respect to a two sided 95% CI-group A vs group B at 6 months	82
Fig. (31)	Primary analysis treatment effect estimates with respect to a two sided 95% CI-group A vs group B at 12 months	83
Fig. (32)	OCT scan (a)before STMPL treatment and (b) after STMPL treatment	85
Fig. (33)	OCT scan of Study eye no.7 at baseline, 3, 6 ,9 and 12 months	88
Fig. (34)	OCT scan of Study eye no.25 at baseline, 3, 6 ,9 and 12 months	89
Fig. (35)	OCT scan of Study eye no.31 at baseline, 3, 6 ,9 and 12 months	90

List of tables

Table No.	Title	Page No.
Table (1)	Laser parameters and application patterns in previous studies	49
Table (2)	Demographic data of the two study groups at baseline	67
Table (3)	Baseline study eye characteristics	69
Table (4)	The mean BCVA (log MAR) at baseline and during each follow up visit	71
Table (5)	Number of lines gained at 3, 6, 9 and 12 months of follow up	72
Table (6)	The mean CST in the two study groups at baseline, 3, 6, 9and 12 months	77
Table (7)	The mean reduction in CST at 3, 6, 9 and 12 months in the two study groups	78
Table (8)	Percentage of reduction in CST at 3, 6, 9 and 12 months in the two study groups	79

Introduction

The management of diabetic macular oedema (DME) has substantially changed over the years due to the advancement in pharmacotherapy with intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF). However, the traditional laser treatment proposed by the Early Treatment Diabetic Retinopathy Study (ETDRS) is still being used for its efficacy, low cost and easy processing.

Despite the improvements and the satisfactory results of laser photocoagulation, adverse events such as central scotoma, loss of central vision, decreased color vision, preretinal and subretinal fibrosis and choroidal neovascularization can still occur, mostly caused by permanent destruction of the photoreceptors and the progressive enlargement of the laser scars, consequent to the visible burn endpoint of conventional threshold laser photocoagulation¹⁻²⁻³⁻⁴.

Results of the diabetic retinopathy clinical research (DRCR) network protocol I trial showed that intravitreal Ranibizumab (a humanized monoclonal antibody fragment which competitively inhibits VEGF in the extracellular space), with prompt or deferred laser was more effective compared with prompt laser alone for the treatment of DME involving the central macula after one year follow up, and that the vision gains were maintained through 5 years follow up with little additional treatment needed after 3 years⁵⁻⁶.

Several other studies have been conducted to investigate the efficacy and safety of Intravitreal Ranibizumab in treatment of DME including the READ-2 study, the RESOLVE study, the

RESTORE study and the RISE and RIDE studies which showed that ranibizumab is effective in improving best corrected visual acuity (BCVA) and is well tolerated in DME⁷⁻⁸⁻⁹⁻¹⁰.

Although Ranibizumab was demonstrated to be effective, a major concern, is that DME will return as the effect of the intravitreal drug lessens, necessitating repetitive long term injections. Another concern is the financial burden of repeated intravitreal injections of ranibizumab. That led to the emergence of new modalities of laser treatment for management of diabetic retinopathy (DR), including selective retinal therapy (SRT) and subthreshold micropulse laser (STMPL) in which the modification of laser parameters and using selective laser wave lengths can produce less destructive and more therapeutic effect.

The state of the art of STMPL has been shown to be effective in the treatment of DME in terms of BCVA, central macular thickness (CMT), and macular sensitivity¹¹⁻¹²⁻¹³⁻¹⁴. STMPL has also been suggested to have anti-inflammatory effects reducing the number of hyper-reflective spots (sign of activated microglia cells in the retina), microaneurysms, disorganization of the inner retinal layers extension, and the area of cysts¹⁵. Also, several prospective randomized trials have reported equal improvement in BCVA and retinal thickness between STMPL and conventional ETDRS laser photocoagulation in DME¹⁶⁻¹⁷⁻¹⁸⁻¹⁹⁻²⁰.

Diabetic macular oedema

DR is a leading cause of vision-loss globally. Of an estimated 285 million people with diabetes mellitus worldwide, approximately one third have signs of DR and of these, a further one third of DR is vision-threatening DR, including DME. DME is responsible for most of the visual loss experienced by patients with diabetes²¹.

Pathophysiology of DME:

DME results from abnormal leakage of fluid and macromolecules, such as lipoproteins, from retinal capillaries (i.e. the inner blood retinal barrier (BRB) as shown in figure 1) into the extravascular space. This is followed by an influx of water into the extravascular space due to increased oncotic pressure²², as shown in figure (2).




Fig.(1). Blood retinal barrier. (A) Schematic representation of the retinal layers with inner BRB and outer BRB. (B) Inner BRB. (C) Outer BRB²³.

The retinal pigment epithelium (RPE) normally acts as a barrier to fluid flow from the choriocapillaris to the retina and also actively pumps fluid out of the retina (i.e. the outer BRB as shown in figure 1). Thus, abnormalities in the RPE may contribute to DME allowing increased fluid access from the choriocapillaries or decreasing the normal efflux of fluid from the retina²².




Fig.(2). Pathophysiological mechanisms leading to macular edema. Macular oedema results from an imbalance between fluid entry and fluid exit, leading to intraretinal or subretinal fluid accumulation, driven by Starling equation²².

Hyperglycemia has been considered as the main cause of the onset and progression of DME and DR²⁴ as shown in figure (3). However, hyperglycemia does not fully explain the wide range of functional and cellular changes that appear over the course of DR.